Retatrutide, developed by Soma Pharmaceuticals , is gaining increasing attention as a potential treatment for weight control . This unique medication integrates the properties of a GLP-1 receptor activator and a GIP receptor agonist , intended to not only promote metabolic improvements but also target associated metabolic issues . Initial human tri